Eun Yang
Stock Analyst at Jefferies
(0.46)
# 4,120
Out of 4,989 analysts
34
Total ratings
31.58%
Success rate
-26.79%
Average return
Main Sectors:
Stocks Rated by Eun Yang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| UTHR United Therapeutics | Maintains: Buy | $315 → $432 | $425.63 | +1.50% | 8 | Sep 23, 2024 | |
| TSHA Taysha Gene Therapies | Assumes: Buy | $2 → $8 | $3.07 | +161.01% | 2 | May 14, 2024 | |
| ATXS Astria Therapeutics | Maintains: Buy | $22 → $27 | $7.13 | +278.68% | 2 | Mar 25, 2024 | |
| RLYB Rallybio | Downgrades: Hold | $7 → $1.5 | $0.56 | +165.72% | 2 | Feb 7, 2024 | |
| BBIO BridgeBio Pharma | Downgrades: Hold | $24 → $33 | $48.94 | -32.56% | 1 | Jul 18, 2023 | |
| BMEA Biomea Fusion | Downgrades: Hold | $36 → $28 | $2.05 | +1,265.85% | 2 | Jun 26, 2023 | |
| ELVN Enliven Therapeutics | Initiates: Buy | $27 | $18.57 | +45.40% | 1 | Mar 29, 2023 | |
| GNSS Genasys | Maintains: Outperform | $6 → $7 | $2.54 | +175.59% | 1 | Feb 10, 2023 | |
| CVAC CureVac | Upgrades: Buy | n/a | $5.36 | - | 2 | Jan 9, 2023 | |
| PRME Prime Medicine | Initiates: Buy | $25 | $5.22 | +378.93% | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $105,000 → $15,000 | $3.88 | +386,497.94% | 1 | Sep 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $2.07 | +1,107.73% | 1 | Nov 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $23.00 | +52.17% | 1 | Jun 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $220 | $271.18 | -18.87% | 3 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $310 | $135.67 | +128.50% | 3 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $80 | $110.99 | -27.92% | 3 | Jul 11, 2017 |
United Therapeutics
Sep 23, 2024
Maintains: Buy
Price Target: $315 → $432
Current: $425.63
Upside: +1.50%
Taysha Gene Therapies
May 14, 2024
Assumes: Buy
Price Target: $2 → $8
Current: $3.07
Upside: +161.01%
Astria Therapeutics
Mar 25, 2024
Maintains: Buy
Price Target: $22 → $27
Current: $7.13
Upside: +278.68%
Rallybio
Feb 7, 2024
Downgrades: Hold
Price Target: $7 → $1.5
Current: $0.56
Upside: +165.72%
BridgeBio Pharma
Jul 18, 2023
Downgrades: Hold
Price Target: $24 → $33
Current: $48.94
Upside: -32.56%
Biomea Fusion
Jun 26, 2023
Downgrades: Hold
Price Target: $36 → $28
Current: $2.05
Upside: +1,265.85%
Enliven Therapeutics
Mar 29, 2023
Initiates: Buy
Price Target: $27
Current: $18.57
Upside: +45.40%
Genasys
Feb 10, 2023
Maintains: Outperform
Price Target: $6 → $7
Current: $2.54
Upside: +175.59%
CureVac
Jan 9, 2023
Upgrades: Buy
Price Target: n/a
Current: $5.36
Upside: -
Prime Medicine
Nov 14, 2022
Initiates: Buy
Price Target: $25
Current: $5.22
Upside: +378.93%
Sep 22, 2022
Maintains: Buy
Price Target: $105,000 → $15,000
Current: $3.88
Upside: +386,497.94%
Nov 2, 2021
Initiates: Buy
Price Target: $25
Current: $2.07
Upside: +1,107.73%
Jun 22, 2021
Initiates: Buy
Price Target: $35
Current: $23.00
Upside: +52.17%
Jul 27, 2018
Maintains: Buy
Price Target: $200 → $220
Current: $271.18
Upside: -18.87%
Jul 11, 2017
Assumes: Hold
Price Target: $310
Current: $135.67
Upside: +128.50%
Jul 11, 2017
Assumes: Hold
Price Target: $80
Current: $110.99
Upside: -27.92%